Q: Pls comment on quarter, forward guidance and current and FY25 valuations. Thx.
5i Research Answer:
Revenue was $243.1M, higher than estimates of $236.7M. EPS was 5c vs 4c estimated. Sales guidance was raised to $970M to $990M for the year. EBITDA guidance was maintained. Sales rose 42% with strong 21% organic growth. Patient visits were 1.4M, up 38%. The conference call is later Wednesday but these results look fine based on the press release.